Brief: Mithra Pharmaceuticals Extends Studies Of Donesta Clinical Program

Mithra Pharmaceuticals SA

29/11/2021 06:43

Nov 29 (Reuters) - Mithra Pharmaceuticals SA  MITRA.BR :
    * CONSOLIDATION OF DONESTA® PRODUCT CANDIDATE
    * MITHRA DECIDED TO BROADEN THE SCOPE OF ITS CLINICAL
PROGRAM BY
LAUNCHING THREE ADDITIONAL STUDIES
    * 1. A PHASE 3 STUDY ON THE EFFECT OF E4 ON VULVOVAGINAL
ATROPHY
(VAGINAL DRYNESS, PAIN DURING INTERCOURSE, URINARY TRACT
INFECTIONS);
    * 2. A PHASE 2 STUDY ON THE EFFECT OF E4 ON SKIN TEXTURE,
QUALITY
AND APPEARANCE;
    * 3. A PHASE 2 STUDY ON THE EFFECT OF E4 ON HAIR TEXTURE,
QUALITY
AND APPEARANCE
    * THESE THREE ADDITIONAL STUDIES FUNDED BY MITHRA FOR AN
AMOUNT OF
APPROXIMATELY EUR 20 MILLION WILL BE LAUNCHED IN 2022, DEPENDING
ON REGULATORY AGENCIES’ FEEDBACK
    * MITHRA ACQUIRES THE RIGHTS RELATING TO TWO DEVELOPMENT
PROGRAMS
LED BY THE BELGIAN COMPANY BCI PHARMA ON INNOVATIVE INHIBITORS
OF CSF1R KINASE
    * THE INNOVATIVE CLASS OF TYROSINE KINASES INHIBITORS
REPRESENTS
THE THIRD FASTEST GROWING THERAPEUTIC CLASS IN 2020, WITH A 17%
INCREASE IN REVENUES TO USD 40.3 BILLION
    * UNDER THE TERMS OF THE CONTRACT, MITHRA HAS AN OPTION TO
ACQUIRE
PATENTS COVERING CSF1R INHIBITOR SERIES WITH UPFRONT PAYMENT OF
EUR 2.25 MILLION ON EXECUTION OF OPTION, FOLLOWING THE FIRST
RESULTS CONDUCTED BY BCI PHARMA
    * CURRENTLY IN THE PRECLINICAL STAGE, BCI PHARMA SHOULD
INITIATE
CLINICAL DEVELOPMENT IN 2023, WITH MARKETING AUTHORIZATIONS
EXPECTED FOR 2031

Source text for Eikon:  ID:nNDL2LlyY0 
Further company coverage:  MITRA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))